Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Sciencast Management LP

Sciencast Management LP grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 35.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,131 shares of the medical equipment provider's stock after buying an additional 2,391 shares during the period. Sciencast Management LP's holdings in Zimmer Biomet were worth $965,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $25,000. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 218 shares during the period. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at approximately $35,000. Kentucky Trust Co purchased a new stake in Zimmer Biomet during the 4th quarter valued at $39,000. Finally, OFI Invest Asset Management bought a new stake in Zimmer Biomet in the fourth quarter worth $40,000. 88.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.95% of the stock is owned by company insiders.

Remove Ads

Zimmer Biomet Stock Down 0.8 %

ZBH stock traded down $0.92 during trading on Tuesday, reaching $110.32. 626,621 shares of the company traded hands, compared to its average volume of 1,496,400. The company has a market capitalization of $21.96 billion, a price-to-earnings ratio of 24.79, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The business has a 50 day simple moving average of $106.86 and a 200 day simple moving average of $106.86. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company posted $2.20 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet's payout ratio is 21.57%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZBH. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. JMP Securities reaffirmed a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus raised their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial reiterated a "hold" rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.